Untitled

Abstract

Objectives: Although direct-acting antiviral agents have revolutionized hepatitis C virus treatment, these novel agents are not widely available in the developing world. Further, no treatment recom mendation for renal transplant recipients includes these agents. We aimed to evaluate the effectiveness of sofosbuvir and ribavirin, the only direct-acting antiviral agents available in Pakistan, in renal transplant recipients.

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

“…We found 29 studies pertaining to KTRs. 29 , 30 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 The studies evaluated the following: GLE/PIB (1 study, N = 20), GZR/EBR (2 studies, N = 21), PrO ± D (2 studies, N = 33), SOF (6 studies, N = 117), SOF/DCV (7 studies, N = 351), SOF/LDV (9 studies, N = 300), and SOF/VEL (1 study, N = 10). Three retrospective, unadjusted studies also compared a variety of DAA regimens ( N = 86), mostly SOF/LDV or SOF/DCV, to no DAA treatment ( N = 63).…”

HCV Treatment with Sofosbuvir in Pakistan; Current Scenario and Future Perspective

“…The detailed analysis of available data suggested a very good response for this DAA antiviral regimen in different cities with overall 80-100% SVR/RVR [13][14][15][16][17][18] . There is also a study which included 37 renal transplant HCV patients from Karachi and sofosbuvir treatment showed 89.2% RVR for these individuals [19] .…”